Dr. James N. Deangelo, D.O.
Allergy & Immunology (Allergy Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 308
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Philadelphia College of Osteopathic Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
PA license OS007667L
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jefferson Hospital Jefferson Hills, PA
- St Clair Hospital Pittsburgh, PA
- Canonsburg General Hospital Canonsburg, PA
- Washington Hospital, the Washington, PA
Medical groups
- Allergy and Clinical Immunology Associates, PC (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 308
- Services billed
- 4,275
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 1,148 | 26 |
| Professional service for preparation and provision of 1 or more antigens | 930 | 54 |
| Professional service for multiple injections of allergen | 330 | 54 |
| Professional service for single injection of allergen | 239 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 127 | 95 |
| Test to measure rate of airflow | 95 | 67 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 44 |
| Administration of influenza virus vaccine | 39 | 39 |
| Established patient office or other outpatient visit, 40-54 minutes | 38 | 29 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 35 | 35 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Pittsburgh, PA | 193 |
| Pantoprazole Sodium Other prescribers in Pittsburgh, PA | 147 |
| Fluticasone Propionate Other prescribers in Pittsburgh, PA | 108 |
| Azelastine Hcl Other prescribers in Pittsburgh, PA | 77 |
| Famotidine Other prescribers in Pittsburgh, PA | 73 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Pittsburgh, PA | 72 |
| Ipratropium Bromide Other prescribers in Pittsburgh, PA | 59 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Pittsburgh, PA | 42 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Pittsburgh, PA | 39 |
| Levocetirizine Dihydrochloride Other prescribers in Pittsburgh, PA | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 144 payments worth $10,923 in total to this clinician.
| Biocryst Pharmaceuticals, Inc. | $8,125 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $484 |
| GlaxoSmithKline, LLC. | $330 |
| Csl Behring | $316 |
| Regeneron Healthcare Solutions, Inc. | $199 |
| Genzyme Corporation | $180 |
| Grifols USA, LLC | $161 |
| Genentech USA, Inc. | $148 |
| Consulting Fee | $6,501 |
|---|---|
| Food and Beverage | $3,018 |
| Travel and Lodging | $1,228 |
| Education | $177 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Biocryst Pharmaceuticals, Inc. Apr 30, 2025 | Consulting Fee ORLADEYO · Immunology | $6,501 |
| Biocryst Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ · in-kind | $357 |
| Biocryst Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ · in-kind | $349 |
| Biocryst Pharmaceuticals, Inc. Mar 27, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ · in-kind | $205 |
| Biocryst Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ · in-kind | $205 |
| Regeneron Healthcare Solutions, Inc. Nov 7, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $99.57 |
| Sanofi-aventis U.S. LLC Sep 5, 2025 | Education DUPIXENT · Immunology · in-kind | $76.99 |
| Biocryst Pharmaceuticals, Inc. Apr 30, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ | $43.40 |
| Biocryst Pharmaceuticals, Inc. Apr 30, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ | $40.00 |
| Biocryst Pharmaceuticals, Inc. Mar 28, 2025 | Travel and Lodging ORLADEYO · Immunology · travel to Jersey City, NJ · in-kind | $29.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $479,463 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP - A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Pharmaceuticals USA, Inc. - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.